Estimation of 24-hour urine protein quantity by the morning-urine protein/creatinine ratio.

BACKGROUND: Many reports have described a correlation between the morning-urine protein /creatinine ratio (morning urine P/Cr) and the quantity of 24-h urine protein (Up), as well as regression formulas for Up with morning-urine P/Cr. However, there is no universal regression formula that can be used at all facilities. It is still controversial whether a qualitative calculation is required at outpatient clinics. To develop a practical and universal method, we used receiver operating characteristic (ROC) analysis to estimate Up from morning-urine P/Cr. METHODS: The subjects were 34 children (309 specimens) with kidney disease who had been admitted to Miyazaki Prefectural Hospital. We examined the correlations of P/Cr with Up and Up/body surface area (Up/BSA) using morning and daytime urine. We determined the cutoff values to estimate Up/BSA from morning-urine P/Cr with an ROC analysis. Next, we applied the values to specimens obtained from other facilities to show the universality of this approach. RESULTS: Up/BSA for samples in one hospital was significantly correlated with morning-urine P/C. When the morning-urine P/Cr ratio is >or=1.0 or >or=2.0, the Up/BSA ratio will exceed 0.5 or 1.0 (g/m(2) per day), respectively, and the efficiency was sufficiently high (efficiency for Up/BSA of >or=0.5: 88.0%, efficiency for Up/BSA of >or=1.0: 90.9%). When we analyzed samples from two other facilities with these cutoff values, both the sensitivity and specificity were greater than 80% for both facilities. CONCLUSIONS: The use of cutoff values of 1.0 and 2.0 for morning-urine P/Cr determined by ROC analysis could be a universal method for quantitatively estimating Up/BSA >or=0.5 and 1.0, respectively.

Immune response to a laminin-binding protein (Lmb) in group A streptococcal infection.

BACKGROUND: A laminin-binding protein (Lmb) similar to that of group B streptococcus is conserved in group A streptococcus (GAS) and has a role in adhesion of GAS to epithelial cells. The role of this protein is yet to be clarified in disease process and thus, it is important to know its role in binding of GAS to laminin and the immunogenic response against it in patients related with GAS infection. METHODS: A recombinant protein (rGAS-Lmb) was purified using the lmb gene from M1 GAS and tested for its role in binding of GAS with laminin. The antibody response against rGAS-Lmb in patient sera related with GAS infection was measured by ELISA. RESULTS: The rGAS-Lmb bound with laminin directly and inhibited the binding of GAS to laminin. The antibody response against rGAS-Lmb in patients with uncomplicated streptococcal infection (U. Strep) and those with rheumatic fever (RF) were significantly higher than those in the control group (P < 0.0001 and P < 0.001, respectively). No difference of anti-rGAS-Lmb antibody titer could be found between these two disease groups. CONCLUSION: The higher antibody response in patients with GAS infection implies that the protein is well expressed during the period of infection and may be related with the colonization and infection of GAS in pharyngeal mucosa.

Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.

BACKGROUND: Mizoribine (MZR) is a novel immunosuppressant developed in Japan. As MZR is reported to be less toxic than other cytotoxic drugs, it is frequently used in Japan in the treatment of adult patients with rheumatoid arthritis or lupus nephritis. The objective of this study was to evaluate the efficacy of MZR in children with SLE. Nine female children with lupus nephritis who had undergone renal biopsy before starting MZR, were involved in this study. Their mean disease duration was 4.8 years at the time MZR treatment was initiated. Patients who had received intensive medications, such as methyl-prednisolone pulse therapy, intravenous cyclophosphamide pulse therapy, and/or other immunosuppressants, within the 4 months prior to the start of the study, were excluded. METHODS: Patients treated with 3 mg/kg per day of MZR were monitored every month for up to 1 year. The efficacy of MZR was evaluated by the changes from baseline values of serum C3, serum C4, anti-dsDNA antibody titer, erythrocyte sedimentation rate (ESR), urinary protein, dosage of prednisolone (PSL), and the sum of the scores defined by these parameters. RESULTS: Favorable changes were observed in C3 and ESR after 2 months and 3 months of MZR therapy, respectively. At 3 months of MZR therapy, the sum of scores defined by the parameters for disease activity indicated that MZR was more effective in non-class IV nephritis patients (n = 5) than in class IV nephritis patients (n = 4) (P = 0.0197). All nine children involved in the study tolerated the MZR therapy well during the study. CONCLUSION: MZR was safe in lupus children, but its efficacy was limited in patients with non-class IV nephritis. Further study is necessary, in which higher dosages and/or earlier use of MZR is provided to a larger number of children.

Characterization of Klebsiella pneumoniae and Escherichia coli strains that produce CTX-M-2-type broad spectrum beta-lactamase isolated from a child with leukemia.

An 8-year-old girl with acute leukemia had bacteremia caused by Klebsiella pneumoniae producing CTX-M-2-type broad spectrum beta-lactamase. K. pneumoniae and Escherichia coli strains producing the same enzyme and harboring identical conjugative plasmids were recovered from stoor culture. Patients with frequent episodes of neutropenia and prophylactic administration of beta-lactams are at risk of harboring colonizing strains that produce broad spectrum beta-lactamases.